A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Trial to Compare the Safety, Pharmacokinetics and Pharmacodynamics of JW0301 to C2105 in Healthy Subjects
Latest Information Update: 25 Mar 2024
At a glance
- Drugs C 2105 (Primary) ; JW 0301 (Primary)
- Indications Unspecified
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors JW Pharmaceutical
- 19 Mar 2024 Status changed from recruiting to completed.
- 05 Jul 2022 New trial record